- Home
- CDW vs RARE Comparison
CDW vs RARE Comparison
Compare CDW & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDW
- RARE
- Stock Information
- Founded
- CDW 1984
- RARE 2010
- Country
- CDW United States
- RARE United States
- Employees
- CDW N/A
- RARE N/A
- Industry
- CDW Catalog/Specialty Distribution
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- CDW Consumer Discretionary
- RARE Health Care
- Exchange
- CDW Nasdaq
- RARE Nasdaq
- Market Cap
- CDW 30.7B
- RARE 5.3B
- IPO Year
- CDW 1993
- RARE 2014
- Fundamental
- Price
- CDW $212.21
- RARE $55.24
- Analyst Decision
- CDW Strong Buy
- RARE Strong Buy
- Analyst Count
- CDW 8
- RARE 15
- Target Price
- CDW $254.63
- RARE $87.47
- AVG Volume (30 Days)
- CDW 965.5K
- RARE 659.0K
- Earning Date
- CDW 10-30-2024
- RARE 10-31-2024
- Dividend Yield
- CDW 1.17%
- RARE N/A
- EPS Growth
- CDW 3.85
- RARE N/A
- EPS
- CDW 8.16
- RARE N/A
- Revenue
- CDW $20,942,900,000.00
- RARE $481,303,000.00
- Revenue This Year
- CDW $1.37
- RARE $26.02
- Revenue Next Year
- CDW $5.47
- RARE $18.78
- P/E Ratio
- CDW $26.00
- RARE N/A
- Revenue Growth
- CDW N/A
- RARE 19.47
- 52 Week Low
- CDW $185.04
- RARE $31.52
- 52 Week High
- CDW $263.37
- RARE $58.73
- Technical
- Relative Strength Index (RSI)
- CDW 38.20
- RARE 59.52
- Support Level
- CDW $221.78
- RARE $54.93
- Resistance Level
- CDW $226.64
- RARE $57.26
- Average True Range (ATR)
- CDW 4.50
- RARE 1.84
- MACD
- CDW -1.10
- RARE -0.40
- Stochastic Oscillator
- CDW 2.54
- RARE 42.79
About CDW CDW Corporation
CDW Corp is a multi-brand provider of information technology ("IT") solutions to small, medium, and large business, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's broad array of offerings ranges from discrete hardware and software products to integrated IT solutions and services that include on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. The company has three operating segments namely, Corporate, Small Business, and Public. The Corporate segment generates the majority of its revenue and primarily serves US private sector business customers with more than 250 employees.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.